Activité, Système Moteur & Coordination
Douleur - Allodynie/Hyperalgésie Thermique
Douleur - Spontanée - Déficit de Posture
Douleur - Allodynie/Hyperalgésie Mécanique
Anxiété & Dépression
Apprentissage/Mémoire - Attention - Addiction
Physiologie & Recherche Respiratoire
Métabolisme & Prise Alimentaire
Douleur
Métabolisme
Système moteur
Neurodégénérescence
Thématiques transversales
Système musculaire
Functions de motricité générale
Troubles de l'humeur
Other disorders
Joints
Système Nerveux Central (SNC) 
Système sensoriel
Authors
S Marmolejo-Mart?nez-Artesero, D Romeo-Guitart et al
Lab
Institut de Neuroci?ncies (INc) and Department of Cell Biology, Physiology and Immunology,Universitat Aut?noma de Barcelona (UAB), Bellaterra, Barcelona, Spain
Journal
Cells
Abstract
Muscle wasting is an unmet medical need which leads to a reduction of myofiber diameter and a negative impact on the functional performance of daily activities. We previously found that a new neuroprotective drug called NeuroHeal reduced muscle atrophy produced by transient denervation. Aiming to decipher whether NeuroHeal has a direct role in muscle biology, we used herein different models of muscle atrophy: one caused by chronic denervation, another caused by hindlimb immobilization, and lastly, an in vitro model of myotube atrophy with Tumor Necrosis Factor-alpha (TNFalpha). In all these models, we observed that NeuroHeal reduced muscle atrophy and that SIRT1 activation seems to be required for that. The treatment downregulated some critical markers of protein degradation: Muscle Ring Finger 1 (MuRF1), K48 poly-Ub chains, and p62/SQSTM1. Moreover, it seems to restore the autophagy flux associated with denervation. Hence, we envisage a prospective use of NeuroHeal at clinics for different myopathies.
